AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Five Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare Conference

December 30, 2019 GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 30, 2019--

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will participate in the 38 th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020. William Ringo, who is Five Prime’s Chairman and interim Chief Executive Officer, will represent the company and respond to questions from investors. He is scheduled to present at 7:30 a.m. PT (10:30 a.m. ET).

Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.fiveprime.com/events-presentations. A replay of the presentation will also be available on the Five Prime website for 30 days after the conference.

About Five Prime

Five Prime Therapeutics, Inc. develops innovative protein therapeutics to improve the lives of patients with cancer. The company focuses on developing immune modulators and precision therapies for solid tumor cancers paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime’s product candidates. The company’s product candidates have innovative mechanisms of action and address patient populations in need of better therapies. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.

Source: Five Prime Therapeutics, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191230005080/en/

CONTACT: Media and Investor Contact

Martin Forrest

VP, Investor Relations & Corporate Communications

Five Prime Therapeutics, Inc.

415-365-5625

martin.forrest@fiveprime.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: Five Prime Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 12/30/2019 01:05 PM/DISC: 12/30/2019 01:05 PM

http://www.businesswire.com/news/home/20191230005080/en